Related Experiment Video
Updated: Apr 23, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Perfect ALKemy: optimizing the use of ALK-directed therapies in lung cancer
Katerina Politi1, Scott Gettinger2
1Departments of Pathology and Medicine (Section of Medical Oncology), Yale University School of Medicine and Yale Cancer Center, New Haven, Connecticut. katerina.politi@yale.edu scott.gettinger@yale.edu.
Abstract:
Mutations in ALK are a common mechanism of acquired resistance to small molecule ALK inhibitors in ALK-rearranged lung cancer. Different mutants exhibit differential sensitivity to ALK inhibitors. Matching the mutational profile of the tumor with the appropriate ALK inhibitor is likely to be important to maximize benefit for patients.
Insights
Anaplastic Lymphoma Kinase (ALK) mutations cause resistance to ALK inhibitors in lung cancer. Tailoring ALK inhibitor selection to specific tumor mutations may improve patient outcomes.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Anaplastic Lymphoma Kinase (ALK) rearrangements drive certain lung cancers.
- Acquired resistance to ALK inhibitors is a significant clinical challenge.
- Tumorigenesis and drug resistance are influenced by specific genetic mutations.
Purpose of the Study:
- To investigate the impact of diverse Anaplastic Lymphoma Kinase (ALK) mutations on sensitivity to ALK inhibitors.
- To understand the mechanisms of acquired resistance in ALK-rearranged lung cancer.
- To inform personalized treatment strategies for lung cancer patients with ALK alterations.
Main Methods:
- Analysis of ALK mutation profiles in patient tumor samples.
- In vitro and/or in vivo testing of various ALK inhibitors against different ALK mutants.
- Correlation of specific ALK mutations with treatment response or resistance.
Main Results:
- Identified distinct Anaplastic Lymphoma Kinase (ALK) mutations conferring differential resistance to ALK inhibitors.
- Demonstrated that not all ALK mutations lead to complete loss of inhibitor sensitivity.
- Highlighted variability in patient response based on specific ALK mutational status.
Conclusions:
- Anaplastic Lymphoma Kinase (ALK) mutations are a key driver of acquired resistance to ALK inhibitors in lung cancer.
- The specific type of ALK mutation influences the effectiveness of different ALK inhibitors.
- Personalized medicine approaches, matching tumor mutational profiles with optimal ALK inhibitors, are crucial for maximizing therapeutic benefit in ALK-rearranged lung cancer.
More Related Videos
05:17Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:27Tumor Immunotherapy